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SUMMARY 
 
 • Autocrine VEGF signaling in tumor cells contributes to 
de-differentiation and function of tumor initiating/stem cells 
• NRP2 is the nexus of a signaling pathway that promotes 
de-differentiation and sustains tumor initiating/stem sells 
 
• Anti-NRP2 therapy is worth pursuing, especially for high-grade 
    cancers.  Therapeutic Abs are available. 
 
